Inhibitors of cell cycle checkpoint target Wee1 kinase - a patent review (2003-2022)

DNA damage repair in most malignancies with mutation of p53 is more dependent on the G2/M checkpoint. Wee1 kinase is a key regulator of the G2/M checkpoint. If Wee1 is inhibited, it results in cells with unrepaired DNA damage entering mitosis prematurely, leading to mitotic catastrophe and subsequen...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Expert opinion on therapeutic patents Jg. 32; H. 12; S. 1217 - 1244
Hauptverfasser:	Yan, Jingxue, Zhuang, Lili, Wang, Yong, Jiang, Yiqing, Tu, Zhenlin, Dong, Chao, Chen, Yadong, Zhu, Yong
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Taylor & Francis 02.12.2022
Schlagworte:	anticancer cell cycle checkpoint Cell Cycle Checkpoints Cell Cycle Proteins Cell Line, Tumor clinical development Humans inhibitors Neoplasms - drug therapy Neoplasms - genetics Patents as Topic Protein-Tyrosine Kinases - genetics Protein-Tyrosine Kinases - metabolism Wee1 kinase clinical development inhibitors patent Wee1 kinase anticancer cell cycle checkpoint
ISSN:	1354-3776, 1744-7674, 1744-7674
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!